{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-26-000006","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.866066+00:00","generated_at":"2026-05-14T23:48:36.524778+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B","bullets":["Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.","GAAP diluted EPS $0.54 vs $0.95; non-GAAP diluted EPS $0.76 vs $1.13.","FY2026 revenue guidance raised to $3.825B-$3.925B, implying ~20% YoY growth at midpoint.","Operating cash flow $221M; closed $3.7B non-convertible debt to fund Amicus acquisition.","Enzyme Therapies revenue up 6% to $514M; VOXZOGO $220M (+3%); $31M charge for NAGLAZYME campaign."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-26-000006","json":"https://secwatch.observer/filing/0001048477-26-000006.json","markdown":"https://secwatch.observer/filing/0001048477-26-000006.md","text":"https://secwatch.observer/filing/0001048477-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/0001048477-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/bmrn-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:48:36.524778+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"984aa6e8ff0205365ce217b2f5ab62b3f6576c48","claim":"BIOMARIN PHARMACEUTICAL INC reported the first quarter ended March 31, 2026 results: revenue $766 million, net income $106 million. Guidance raised.","evidence_excerpt":"Total Revenues for the first quarter of 2026 were $766 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/0001048477-26-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$766 million"},{"label":"Net income","value":"$106 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}